ESC 365 - Evaluating off-target drug effects seen in RCTs using proteomics and mendelian randomisation

ESC Premium Access

Evaluating off-target drug effects seen in RCTs using proteomics and mendelian randomisation

Session: Pharmacogenomics, cardio-omics, and cardiovascular drugs

Topic: Cardiotoxicity of Drugs

Speaker: Ms J. Brody (Seattle, US)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Ms Jennifer Brody

University of Washington, Seattle (United States of America)

0 follower

7 more presentations in this session

Potential use of pharmacogenetics in cardiology: genome-wide association studies of amiodarone-induced thyroid disorders

Speaker: Mr S. Rand (Copenhagen, DK)

Pharmacogenomics of CRP response to statins: a GIST consortium study

Speaker: Doctor E. Magavern (London, GB)

Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis

Speaker: Doctor M. Galli (Rome, IT)

Real-world implementation of a genotype-guided p2y12-inhibitor de-escalation strategy in acute coronary syndrome patients

Speaker: Doctor J. Azzahhafi (Nieuwegein, NL)

Limited visibility and uptake of the clopidogrel pharmacogenomic guidelines among cardiologists

Speaker: Doctor L. Venetucci (Manchester, GB)

Access the full session

Pharmacogenomics, cardio-omics, and cardiovascular drugs

Speakers: Ms J. Brody, Mr S. Rand, Doctor E. Magavern, Doctor M. Galli, Doctor J. Azzahhafi...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources